Indus Gene Expressions Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
- Paid Up Capital ₹ 92.83 Cr
- Company Age 18 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 32.63 Cr
- Satisfied Charges ₹ 30.40 Cr
- Revenue Growth 1429.59%
- Profit Growth -48.25%
- Ebitda -1122.12%
- Net Worth 25.80%
- Total Assets 17.94%
About Indus Gene Expressions
Indus Gene Expressions Limited (IGEL) is a Public Limited Indian Non-Government Company incorporated in India on 09 February 2007 and has a history of 18 years. Its registered office is in Ananthapur, Andhra Pradesh, India.
The Corporate was formerly known as Sri Balaji Biopharmaceuticals India Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 92.83 Cr.
The company currently has active open charges totaling ₹32.63 Cr. The company has closed loans amounting to ₹30.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Indus Gene Expressions Limited India are Neha Agarwal as COMPANY SECRETARY and Usharani C as Cfo. Rupana Nallari, Channa C, Usharani C, and Three other members serve as directors at the Company.
Company Details
- Location
Ananthapur, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231AP2007PLC113311
- Company No.
113311
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Indus Gene Expressions?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neha Agarwal | Company Secretary | 11-May-2024 | Current |
Usharani C  | CFO | 03-Apr-2019 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rupana Nallari  | Director | 07-Oct-2013 | Current |
| Channa C | Director | 06-Nov-2008 | Current |
| Usharani C | Director and Cfo | 01-Jan-2009 | Current |
| Himadeep Nallavadla | Director | 27-Apr-2013 | Current |
| Meka Reddy | Additional Director | 06-May-2022 | Current |
| Avula Reddy | Additional Director | 28-Oct-2019 | Current |
Financial Performance of Indus Gene Expressions.
Indus Gene Expressions Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1429.59% increase. The company also saw a substantial fall in profitability, with a 48.25% decrease in profit. The company's net worth Soared by an impressive increase of 25.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indus Gene Expressions?
In 2022, Indus Gene Expressions had a promoter holding of 44.22% and a public holding of 55.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Xemx Projects Private LimitedHimadeep Nallavadla is a mutual person
Pennzymes International Private LimitedChanna C is a mutual person
- Dr.Reddy Solar Energy And Systems Private Limited
Channa C and Usharani C are mutual person
- Vaikha Llp
Himadeep Nallavadla is a mutual person
- Vishnuka Power Private Limited
Himadeep Nallavadla is a mutual person
- Poorva Solar Power Private Limited
Himadeep Nallavadla is a mutual person
Charges (Loans)
₹32.63 Cr
₹30.40 Cr
Charges Breakdown by Lending Institutions
- Syndicate Bank : 29.00 Cr
- Canara Bank : 3.63 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Sep 2020 | Canara Bank | ₹3.63 Cr | Open |
| 21 Dec 2019 | Syndicate Bank | ₹29.00 Cr | Open |
| 13 Oct 2014 | Andhra Bank | ₹30.40 Cr | Satisfied |
How Many Employees Work at Indus Gene Expressions?
Unlock and access historical data on people associated with Indus Gene Expressions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indus Gene Expressions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indus Gene Expressions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
